Corvus Pharmaceuticals (CRVS) Operating Income (2015 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Operating Income of -$14.9 million for Q1 2026, down 49.94% year-over-year from -$29.7 million in Q1 2025, and down 40.72% quarter-over-quarter from -$10.6 million in Q3 2025.
Corvus Pharmaceuticals (CRVS) Operating Income (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Operating Income history runs 12 years deep, the most recent figure standing at -$14.9 million for Q1 2026.
- In Q1 2026, Operating Income fell 49.94% year-over-year to -$14.9 million; the TTM figure through Mar 2026 stood at -$45.6 million (down 55.39% YoY), while the FY2023 annual figure was -$23.4 million, up 28.12% from the prior year.
- Operating Income for Q1 2026 stood at -$14.9 million, down from -$10.6 million in the prior quarter.
- The five-year high for Operating Income was -$5.6 million in Q3 2023, with the low at -$14.9 million in Q1 2026.
- The 5-year median for Operating Income is -$7.0 million (2022), against an average of -$8.1 million.
- The sharpest annual moves came in 2023 and 2025: Operating Income surged 55.42% in 2023, then plunged 72.87% in 2025.
- Corvus Pharmaceuticals' Operating Income stood at -$5.7 million in 2022, then climbed by 0.26% to -$5.7 million in 2023, then decreased by 28.38% to -$7.3 million in 2024, then plunged by 45.72% to -$10.6 million in 2025, then slumped by 40.72% to -$14.9 million in 2026.
- Business Quant data shows CRVS's Operating Income at -$14.9 million in Q1 2026, -$10.6 million in Q3 2025, and -$10.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Corvus Pharmaceuticals | 1.25 Bn | 1.04 Bn | - | -19.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.30 Mn |
| Mar 31, 2026 | -14.88 Mn |
| Sep 30, 2025 | -10.57 Mn |
| Jun 30, 2025 | -10.26 Mn |
| Mar 31, 2025 | -9.92 Mn |
| Sep 30, 2024 | -7.26 Mn |
| Jun 30, 2024 | -5.94 Mn |
| Mar 31, 2024 | -6.25 Mn |
| Dec 31, 2023 | -5.65 Mn |
| Sep 30, 2023 | -5.56 Mn |
| Jun 30, 2023 | -5.62 Mn |
| Mar 31, 2023 | -6.57 Mn |
| Dec 31, 2022 | -5.67 Mn |
| Sep 30, 2022 | -12.47 Mn |
| Jun 30, 2022 | -7.01 Mn |
| Mar 31, 2022 | -7.41 Mn |
| Dec 31, 2021 | -6.81 Mn |
| Sep 30, 2021 | -9.05 Mn |
| Jun 30, 2021 | -11.29 Mn |
| Mar 31, 2021 | -11.48 Mn |